FBLG vs. PTGX, EWTX, EVO, TARO, ARDX, SDGR, KURA, DVAX, MORF, and AVDL
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Protagonist Therapeutics (PTGX), Edgewise Therapeutics (EWTX), Evotec (EVO), Taro Pharmaceutical Industries (TARO), Ardelyx (ARDX), Schrödinger (SDGR), Kura Oncology (KURA), Dynavax Technologies (DVAX), Morphic (MORF), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry.
Protagonist Therapeutics (NASDAQ:PTGX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
FibroBiologics' return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
Protagonist Therapeutics presently has a consensus target price of $38.00, suggesting a potential upside of 34.99%. Given FibroBiologics' higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than FibroBiologics.
98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.4% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
FibroBiologics has lower revenue, but higher earnings than Protagonist Therapeutics.
In the previous week, Protagonist Therapeutics had 3 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 1 mentions for FibroBiologics. Protagonist Therapeutics' average media sentiment score of 1.19 beat FibroBiologics' score of 0.71 indicating that FibroBiologics is being referred to more favorably in the news media.
Protagonist Therapeutics received 261 more outperform votes than FibroBiologics when rated by MarketBeat users.
Summary
Protagonist Therapeutics beats FibroBiologics on 9 of the 11 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
